Expression and Significance of Cyclin-Dependent Protein Kinase 6 in Diffuse Large B-Cell Lymphoma.
bioinformatics analysis
cyclin-dependent protein kinase 6
diffuse large B-cell lymphoma
prognosis
Journal
International journal of general medicine
ISSN: 1178-7074
Titre abrégé: Int J Gen Med
Pays: New Zealand
ID NLM: 101515487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
07
2022
accepted:
22
08
2022
entrez:
22
9
2022
pubmed:
23
9
2022
medline:
23
9
2022
Statut:
epublish
Résumé
To study the relationship between cyclin-dependent protein kinase 6 (CDK6) expression in diffuse large B-cell lymphoma (DLBCL) and the clinical biological behavior and prognosis. Data mining was performed using the Oncomine and The Cancer Genome Atlas (TCGA) databases to analyze the expression level of CDK6 in DLBCL. CDK6 alterations in DLBCL and related functional networks were analyzed with c-BioPortal and the Gene Set Enrichment Analysis was performed by using DAVID and FunRich software. In addition, screening for differential gene expression of CDK6 was done and enriched by using LinkedOmics. Finally, formalin-fixed and paraffin-embedded (FFPE) tissue samples from 102 patients with DLBCL were collected from the Department of Pathology, Shanxi Cancer Hospital (Taiyuan, Shanxi, China) from January 2015 through December 2020. All cases had complete clinical course records. Thirty cases of lymph node reactive hyperplasia tissues were used as controls. The expression of CDK6 in DLBCL tissues was detected by qRT‑PCR and immunohistochemistry. Bioinformatics analysis: The data showed that mRNA expression level and DNA copy number variations (CNVs) of CDK6 were significantly higher in DLBCL as compared to normal tissue (P ˂ 0.05). Based on C-BioPortal analysis, we speculated that amplification was the most common copy of CDK6 CNV in DLBCL. Through Gene Ontology (GO) analysis of these genes, it was found that the proteins were mainly located in the nucleus and cytoplasm. The biological interaction network of CDK6 alterations were found to participate primarily in the G1-S phase of the process. Analysis of LinkedOmics mRNA sequencing data showed that three genes were positively correlated with CDK6 expression: PSMD1, C2orf29 and ASB1. Through experimental verification, we found that CDK6 was overexpressed in DLBCL, and the expression of CDK6 mRNA and protein in DLBCL were positively correlated with Ann Arbor staging and IPI score (P<0.05), and negatively correlated with overall survival (P<0.001). Data mining results and experiments revealed and confirmed multi-level evidence for the importance of CDK6 in DLBCL; hence, CDK6 may be a potential marker in DLBCL. Thus, our study will perhaps lay the foundation for further research on the role of CDK6 in the genesis and development of DLBCL.
Identifiants
pubmed: 36133914
doi: 10.2147/IJGM.S380496
pii: 380496
pmc: PMC9483138
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7265-7276Informations de copyright
© 2022 Li et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
J Invest Dermatol. 2003 May;120(5):865-70
pubmed: 12713594
Nat Struct Biol. 2002 Mar;9(3):177-81
pubmed: 11828325
N Engl J Med. 2002 Jun 20;346(25):1937-47
pubmed: 12075054
Oncol Rep. 2019 Jul;42(1):321-327
pubmed: 31059102
Med Oncol. 2012 Jun;29(2):856-63
pubmed: 21264532
Blood. 2022 Sep 15;140(11):1229-1253
pubmed: 35653592
J Clin Oncol. 2005 Jun 20;23(18):4117-26
pubmed: 15867204
Oncol Lett. 2012 Jul;4(1):43-46
pubmed: 22807957
Mol Biosyst. 2009 Dec;5(12):1512-26
pubmed: 20023718
Br J Cancer. 1999 Oct;81(4):705-11
pubmed: 10574260
Blood. 2011 Jun 9;117(23):6120-31
pubmed: 21508411
BMC Complement Med Ther. 2021 Jun 4;21(1):163
pubmed: 34088288
Protein Cell. 2016 Jun;7(6):434-44
pubmed: 27230400
Nucleic Acids Res. 2018 Jan 4;46(D1):D956-D963
pubmed: 29136207
Cancer Cell. 2013 Aug 12;24(2):167-81
pubmed: 23948297
Neoplasia. 2007 Feb;9(2):166-80
pubmed: 17356713
Bioinformatics. 2018 Jun 15;34(12):2126-2128
pubmed: 29415173
Mamm Genome. 1999 Jul;10(7):764-7
pubmed: 10384057
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cell. 2004 Aug 20;118(4):493-504
pubmed: 15315761
J Exp Med. 2008 Sep 29;205(10):2251-68
pubmed: 18794340
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Mol Cancer. 2015 Mar 11;14:57
pubmed: 25889927
Leukemia. 2008 Feb;22(2):387-92
pubmed: 17989712
Mol Cell. 2014 Jan 23;53(2):193-208
pubmed: 24389100
Trends Biochem Sci. 2005 Nov;30(11):630-41
pubmed: 16236519
Clin Oral Investig. 2016 Jan;20(1):57-63
pubmed: 25929813